JPRN-UMIN000030372已完成2 期
Phase II study of ramucirumab and irinotecan combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer - HGCSG 1603
Hokkaido Gastrointestinal Cancer Study Group (HGCSG)0 个研究点目标入组 35 人开始时间: 2017年12月13日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
Progression-free survival rate at 6 months was 26.5% (95%CI, 13.2-41.8%, P = 0.1353). This study did not meet its primary endpoint.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Major surgery within 28 days before registration. 2. The patient has a history of DVT, PE, or any other significant thromboembolism during the 3 months prior. 3. Administration of anticoagulant therapy such as warfarin and LMWH. 4. The patient is receiving chronic therapy with nonsteroidal anti-inflammatory agents or other anti-platelet agents. 5. Have documented brain metastases, leptomeningeal disease or uncontrolled spinal cord compression. 6. Diagnosis of arterial hypertension that cannot be controlled with standard medical management. 7. The patient has a serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to first dose of protocol therapy. 8. Primary cancers diagnosed within the previous five years. 9. The patient has symptomatic congestive heart failure or symptomatic or poorly controlled cardiac arrhythmia. 10. The patient has experienced any arterial thrombotic event within 6 months prior. 11. Serious complications or comorbidities. 12. The patient has experienced any Grade 3-4 GI bleeding within 3 months prior to first dose of protocol therapy. 13. History of gastrointestinal perforation and/or fistulae within 6 months prior to registration. 14. Pericardial or pleural effusion or ascites requiring treatment including drainage. 15. Pregnancy, breast-feeding, or plans of pregnancy. 16. Local or systemic active infection requiring treatment; however, HBs-Ag positive patients controlled by nucleic acid analogs and those confirmed as HBV DNA can be enrolled. 17. Current or recent treatment with another investigational drug or participation in another interventional clinical trial. 18. Have known allergy or hypersensitivity to any components of study treatment. 19. The patient has: cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis. 20. Participation in the clinical trial is determined as unsuitable.
研究者
相似试验
已完成
2 期
A Study of Cixutumumab (IMC-A12) in Islet Cell CancerCarcinomaNeuroendocrine TumorsNCT00781911Eli Lilly and Company43
已完成
2 期
A multicenter phase II study of S-1+ramucirumab as first line treatment in elderly patients with advanced/recurrent gastric cancer(KSCC1701)gastric cancerJPRN-jRCTs071180066Suyama Koichi48
进行中（未招募）
2 期
A phase II trial of ramucirumab plus irinotecan for patients with early relapced gastric cancerGastric cancer, early relapse, irinotecan, ramucirumabD013274Gastric cancerJPRN-jRCTs051190071YAMAGUCHI Toshifumi40
已完成
2 期
HGCSG1603gastric cancerJPRN-jRCTs011180029Komatsu Yoshito35
进行中（未招募）
2 期
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer PatientsStomach NeoplasmGastroesophageal Junction AdenocarcinomaGastric CancerStomach CancerNCT03760822Federation Francophone de Cancerologie Digestive112